Study to check the efficacy and safety of topical Tofacitinib gel/ ointment with topical Tacrolimus gel/ ointment in facial vitiligo.
Phase 4
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2024/02/062420
- Lead Sponsor
- Dr Imran Majid
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with a confirmed diagnosis of Facial vitiligo for any duration, Body surface area involvement <5%, Washout period of 1 week in case of topical therapy for Vitiligo and 1 month
washout period for Systemic therapy for vitiligo before enrolment, Written informed consent signed by the patient or legally acceptable
representative(s) in line with applicable regulation of country, Planned treatment in line with the Summary of Product Characteristics
Exclusion Criteria
any contraindication to any of the topical medications, women of childbearing age, pregnancy, lactation, hypersensitivity to any of the topical agents, unwillingness to conform to study protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method